De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.
Basel AbdelazeemJoseph ShehataKirellos Said AbbasNahla Ahmed El-ShahatNischit BaralGovinda AdhikariHafiz Muhammad Waqas KhanMustafa HassanPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2021)
Among patients with ACS treated with PCI, a de-escalation strategy (prasugrel or ticagrelor to clopidogrel) is associated with lower ischemic and bleeding events (net clinical benefits) and lower BARC type 2 or higher bleeding; however, due to the limited number of included studies, further high-quality studies are needed to establish the clinical efficacy of the de-escalation strategy.
Keyphrases
- percutaneous coronary intervention
- acute coronary syndrome
- st segment elevation myocardial infarction
- antiplatelet therapy
- st elevation myocardial infarction
- atrial fibrillation
- acute myocardial infarction
- open label
- coronary artery bypass grafting
- coronary artery disease
- case control
- coronary artery bypass
- clinical trial
- oxidative stress
- left ventricular
- double blind